Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study-Reference-Cited by-同舟云学术

Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study

Published:2021-07-28 Issue:10 Volume:37 Page:1769-1778
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Taniguchi Hiroya¹²,Yoshino Takayuki¹,Yamaguchi Kensei³,Yamazaki Kentaro⁴,Nixon Andrew B.⁵,Tabernero Josep⁶,Van Cutsem Eric⁷,Robling Kim R.⁸,Abada Paolo B.⁹,Hozak Rebecca R.¹⁰,Siegel Robert¹¹^ORCID,Fill Jeffrey A.⁸,Wijayawardana Sameera¹²,Walgren Richard A.⁹,Giles Brendan¹³,Jones Abby¹³,Pitts Kelly R.¹³,Drove Nora⁹,Muro Kei²

Affiliation:

1. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

2. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

3. Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

4. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shunt-gun, Japan

5. Department of Medicine, Duke University School of Medicine, Durham, NC, USA

6. Medical Oncology Department, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain

7. Digestive Oncology, University Hospitals Leuven and Kuleuven, Leuven, Belgium

8. Clinical Diagnostics Laboratory, Eli Lilly and Company, Indianapolis, IN, USA

9. Oncology Division, Eli Lilly and Company, Indianapolis, IN, USA

10. Oncology Business Unit – Patient Tailoring & Global Strategic Planning, Eli Lilly and Company, Indianapolis, IN, USA

11. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

12. Statistics – Oncology, Eli Lilly and Company, Indianapolis, IN, USA

13. Corgenix Inc., Broomfield, CO, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1940908

Reference24 articles.

1. World Health Organization [Internet]. Cancer. Fact Sheets, Vol. 12. Geneva (Switzerland): World Health Organization; 2018 [cited 2020 June 06]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

2. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents

3. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study;Clinical Colorectal Cancer;2024-06

2. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16;ESMO Open;2023-10

3. Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors;International Journal of Molecular Sciences;2023-05-08